Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS Free cash flow margin

Discontinued — last reported Q4 '13

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-187.2%-85.4pp
AbbVie logo
AbbVieABBV
31.8%+5.0pp
Immunome logo
ImmunomeIMNM
-5,118.9%-8,601pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-406%—
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-212%-95.8pp

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0×0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

free cash flow/total revenue=-300.5%

Based on trailing twelve months.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-K/A, filed April 15, 2016. Open the filing →

Filed
Apr 15, 2016, 5:25 PM EDT
Fiscal year
FY2015
Accession
0001390478-16-000095

FAQ

What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.